Table 4.

Outcome according to ALC, risk group, and MRD

Variable	N	5-yr EFS	P-value	5-yr OS	P-value
ALC			.053		.023
< 500 cells/μl	34	76.5 ± 7.6		82.4 ± 6.8
≥ 500 cells/μl	365	88.0 ± 1.8		95.0 ± 1.2
ALC in initial low-risk patients			.580		.319
ALC < 500 cells/μl	10	90.0 ± 10.1		90.0 ± 10.1
ALC ≥ 500 cells/μl	213	94.2 ± 1.7		98.6 ± 0.8
ALC in initial S/H-risk patients			.336		.182
ALC < 500 cells/μl	24	70.8 ± 9.3		79.2 ± 8.3
ALC ≥ 500 cells/μl	152	79.2 ± 3.5		90.0 ± 2.5
ALC in MRD-negative patients			.065		.036
ALC < 500 cells/μl	19	78.9 ± 10.0		84.2 ± 8.9
ALC ≥ 500 cells/μl	299	92.2 ± 1.7		97.3 ± 1.0
ALC in MRD-positive patients			.875		.887
ALC < 500 cells/μl	13	69.2 ± 12.1		76.9 ± 11.1
ALC ≥ 500 cells/μl	64	68.0 ± 6.2		84.4 ± 4.7

ALC, absolute lymphocyte count; S/H, standard/high; MRD, minimal residual disease; EFS, event-free survival; OS, overall survival